RxDoctor Payments Data

Arita McCoy

Nurse Practitioner · Baltimore, MDNPI 1285087379

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,753 of the $7,193 with a category attached, or 66.1%. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 38.7% of the total. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,193in general payments, 2019–2025

Across 32 payments — averaging $224.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$3K
  • Tanabe Pharma America, Inc.$1K
  • AbbVie$961
  • Acorda Therapeutics, Inc$816
  • Amneal Pharmaceuticals LLC$718
  • Acadia Pharmaceuticals Inc$372
  • plus $132 from 2 others

What the payments were for

  • Consulting fees$4,75366%
  • Speaking & faculty fees$70010%
  • Food & beverage$1,73424%
  • Education$60%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,193 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$734
Medicare patients
11
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$40,320
JardianceEmpagliflozin17$21,041
MyrbetriqMirabegron14$6,892
Atorvastatin Calcium93$1,643
Carbidopa-LevodopaCarbidopa/Levodopa21$1,478
Rasagiline Mesylate11$1,366
Allopurinol32$1,232
Mirtazapine40$1,059
Duloxetine Hcl15$793
Nifedipine ErNifedipine22$780
Losartan Potassium48$779
Escitalopram Oxalate44$750
Amlodipine Besylate75$750
Albuterol Sulfate HfaAlbuterol Sulfate30$730
Gabapentin51$705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$718$29721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →